- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis;...
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION24 OCTOBER 2024 at 19.50 EEST Inside information: Orion terminates ODM-111 development program...
WINNIPEG, MB / ACCESSWIRE / October 24, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused...
CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top...
DELRAY BEACH, Fla., Oct. 24, 2024 /PRNewswire/ -- The global pharmaceutical drying equipment market is projected to reach USD 8.18...
Verified Market Research® a leading provider of business intelligence and market analysis is thrilled to announce the release of its...
DEERFIELD, Ill. and PLEASANTON, Calif., Oct. 24, 2024 /PRNewswire/ -- Walgreens (Nasdaq: WBA), an integrated healthcare, pharmacy, and retail leader, and Veeva...
Phase 1 results demonstrate rapid absorption and response profile, highlighting Nasdepi® as an innovative alternative for emergency allergy treatment RALEIGH,...
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ACCESSWIRE / October 24, 2024...
CHATHAM, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage...
Additional real-world studies show sustained HAE attack rate reduction after initiating ORLADEYO, regardless of C1-INH status, and patient preference for...
Completed OAS challenge study meets both primary and secondary endpointsDemonstrates rapid resolution of allergen-related symptoms beginning two minutes after administration...
New patient-reported outcome data from INTEGUMENT-1 and -2 demonstrate that ZORYVE cream 0.15% rapidly decreased the impact of atopic dermatitis...
– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models...
PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company...
- Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important and statistically...
New clinical data from Phio's on-going Phase 1b trial to be presentedMarlborough, Massachusetts--(Newsfile Corp. - October 24, 2024) - Phio...
New clinical data from Phio's on-going Phase 1b trial to be presentedMarlborough, Massachusetts--(Newsfile Corp. - October 24, 2024) - Phio...
BEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development...
BEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development...